Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells.

BMC Cancer
Fariborz Rashid-KolvearSusan J Done

Abstract

Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years, more specific targeted therapies have been introduced. It is known that telomerase is active in over 90% of breast cancer tumors but inactive in adjacent normal tissues. The prevalence of active telomerase in breast cancer patients makes telomerase an attractive therapeutic target. Recent evidence suggests that telomerase activity can be suppressed by peroxisome proliferator activated receptor gamma (PPARgamma). However, its effect on telomerase regulation in breast cancer has not been investigated. In this study, we investigated the effect of the PPARgamma ligand, troglitazone, on telomerase activity in the MDA-MB-231 breast cancer cell line. Real time RT-PCR and telomerase activity assays were used to evaluate the effect of troglitazone. MDA-MB-231 cells had PPARgamma expression silenced using shRNA interference. We demonstrated that troglitazone reduced the mRNA expression of hTERT and telomerase activity in the MDA-MB-231 breast cancer cell line. Troglitazone reduced telomerase activity even in...Continue Reading

References

Dec 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·T HunterW Eckhart
Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·R C AllsoppC B Harley
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·H W SharmaR Narayanan
Jul 16, 1996·Biochemical and Biophysical Research Communications·A ElbrechtJ Berger
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·L NaldiniI M Verma
Jan 7, 1997·Proceedings of the National Academy of Sciences of the United States of America·P TontonozB M Spiegelman
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
Jul 14, 1998·Molecular Cell·E MuellerB M Spiegelman
Oct 10, 1998·Journal of Virology·T DullL Naldini
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L A CareyS Sukumar
Sep 14, 2000·Proceedings of the National Academy of Sciences of the United States of America·E MuellerP W Kantoff
Jan 3, 2001·Nature Medicine·K J MooreM W Freeman
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Apr 25, 2003·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·K L KirkpatrickK Mokbel
May 3, 2003·Breast Cancer Research and Treatment·Lisa D YeeVictoria L Seewaldt
Feb 28, 2004·The Journal of Pharmacology and Experimental Therapeutics·Nicol StrakovaZdenek Kolar
Jun 24, 2004·British Journal of Cancer·C M PerksJ M P Holly
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesco TurturroTomas Welbourne
Feb 11, 2005·Proceedings of the National Academy of Sciences of the United States of America·Howard Y ChangMarc J van de Vijver
Dec 20, 2005·Cell·Michael Lehrke, Mitchell A Lazar
Apr 25, 2006·Molecular and Cellular Biochemistry·Deepak KaulAmit Khanna
Jul 6, 2006·Apoptosis : an International Journal on Programmed Cell Death·Kerstin SchultzeWilfried Roth
Dec 6, 2006·Cancer·Emad A RakhaIan O Ellis
Feb 24, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y-C YangI-P Choung
May 8, 2007·Cancer Cell·Geoffrey D GirnunBruce M Spiegelman
Jun 21, 2007·Molecular Cancer Research : MCR·Fu-Sheng ChouJoseph J Pinzone

❮ Previous
Next ❯

Citations

Apr 25, 2012·Cancer Causes & Control : CCC·Adedayo A OnitiloSuhail A Doi
Nov 25, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X HeS-C J Yeung
Apr 1, 2011·British Journal of Pharmacology·Jihan Youssef, Mostafa Badr
Apr 28, 2016·Pharmacology & Therapeutics·Yinnan Chen, Yanmin Zhang
Jul 28, 2016·Genes·Kathrin Jäger, Michael Walter
Apr 16, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Matthew J DurandAndreas M Beyer

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
FCS

Software Mentioned

Image J

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.